EUCAST technical note on posaconazole

Pharmacokinetics and Absorption of Posaconazole Oral Suspension under Various Gastric Conditions in Healthy Volunteers

Krishna, G., Moton, A., Ma, L., Medlock, M. M., & McLeod, J. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01034-08 · Cited by 348 · see citing works

A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDS

Vázquez, J. A., Skiest, D. J., Nieto, L., Northland, R., Sanne, I., Gogate, J. P., Greaves, W. L., & ISAACS, R. E. (2006) · Clinical Infectious Diseases · doi:10.1086/501457 · Cited by 171 · see citing works

Posaconazole for the Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Subjects with HIV Infection

Skiest, D. J., Vazquez, J. A., Anstead, G. M., Graybill, J. R., Reynes, J., Ward, D., Hare, R., Boparai, N., & Isaacs, R. (2007) · Clinical Infectious Diseases · doi:10.1086/511039 · Cited by 162 · see citing works

Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection

Krishna, G., Sansone‐Parsons, A., Martinho, M., Kantesaria, B. S., & Pedicone, L. D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00454-06 · Cited by 155 · see citing works

Safety and Efficacy of Posaconazole in the Long-Term Treatment of Azole-Refractory Oropharyngeal and Esophageal Candidiasis in Patients with HIV Infection

Vázquez, J. A., Skiest, D. J., Tissot‐Dupont, H., Lennox, J. L., Boparai, N., & Isaacs, R. (2007) · HIV Clinical Trials · doi:10.1310/hct0802-86 · Cited by 66 · see citing works

Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers

Krishna, G., Ma, L., Vickery, D., Yu, X. Y., Wu, I., Power, E., Beresford, E., & Komjathy, S. F. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00889-09 · Cited by 55 · see citing works

Antifungal Susceptibility Testing: Current Approaches

Berkow, E. L., Lockhart, S. R., & Ostrosky‐Zeichner, L. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00069-19 · Cited by 394 · see citing works

ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.

Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12038 · Cited by 386 · see citing works

Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

Cendejas‐Bueno, E., Kolecka, A., Alastruey‐Izquierdo, A., Theelen, B., Groenewald, M., Kostrzewa, M., Cuenca‐Estrella, M., Gómez‐López, A., & Boekhout, T. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.02248-12 · Cited by 234 · see citing works

National Surveillance of Fungemia in Denmark (2004 to 2009)

Arendrup, M. C., Bruun, B., Christensen, J. J., Fuursted, K., Johansen, H. K., Kjældgaard, P., Knudsen, J. D., Kristensen, L., Møller, J., Nielsen, L., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.01811-10 · Cited by 223 · see citing works

Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme

Arendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206 · see citing works

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole

Espinel-Ingroff, A., Pfaller, M. A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., Gonzalez, G. M., Lass-Flörl, C., Lockhart, S. R., Martin-Mazuelos, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-13 · Cited by 105 · see citing works

Enfermedades Infecciosas y Microbiología Clínica

Viasus, D., Antón, A., Pumarola, T., & Carratalà, J. (2016) · Cited by 90 · see citing works

Recent Perspectives in the Management of Fungal Keratitis

Raj, N., Vanathi, M., Ahmed, N. H., Gupta, N., Lomi, N., & Tandon, R. (2021) · Journal of Fungi · doi:10.3390/jof7110907 · Cited by 89 · see citing works

ECIL-3 classical diagnostic procedures for the diagnosis of invasive fungal diseases in patients with leukaemia

Arendrup, M. C., Billé, J., Dannaoui, É., Ruhnke, M., Heussel, C. P., & Kibbler, C. C. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.246 · Cited by 88 · see citing works

Identification of Pathogenic Rare Yeast Species in Clinical Samples: Comparison between Phenotypical and Molecular Methods

Cendejas‐Bueno, E., Gómez‐López, A., Mellado, E., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00336-10 · Cited by 67 · see citing works

Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi‐centre study

Schmalreck, A., Willinger, B., Haase, G., Blum, G., Lass‐Flörl, C., Fegeler, W., Becker, K., & for the Antifungal Susceptibility Testing (AFST) Study Group (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02165.x · Cited by 57 · see citing works

Rapid Susceptibility Testing and Microcolony Analysis of Candida spp. Cultured and Imaged on Porous Aluminum Oxide

Ingham, C. J., Boonstra, S., Levels, S., de Lange, M., Meis, J. F. G. M., & Schneeberger, P. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033818 · Cited by 51 · see citing works

Susceptibility Test Methods: Yeasts and Filamentous Fungi

Johnson, E. M., & Arendrup, M. C. (2015) · ASM Press eBooks · doi:10.1128/9781555817381.ch131 · Cited by 45 · see citing works

Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies

Durgun, M. E., Kahraman, E., Hacıoğlu, M., Güngör, S., & Özsoy, Y. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00974-x · Cited by 42 · see citing works

Acquisition of cross-azole tolerance and aneuploidy in <i>Candida albicans</i> strains evolved to posaconazole

Kukurudz, R. J., Chapel, M., Wonitowy, Q., Adamu Bukari, A.-R., Sidney, B., Sierhuis, R., & Gerstein, A. C. (2022) · G3 · doi:10.1093/g3journal/jkac156 · Cited by 35 · see citing works

Influence of cancer treatment on the Candida albicans isolated from the oral cavities of cancer patients

Ramla, S., Sharma, V., & Patel, M. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-3035-8 · Cited by 35 · see citing works

Interactions of Yeasts, Moulds, and Antifungal Agents

Hall, G. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5 · Cited by 33 · see citing works

EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing

Espinel‐Ingroff, A., Cuenca‐Estrella, M., & Cantón, E. (2013) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0125-7 · Cited by 32 · see citing works

InCandida albicans, resistance to flucytosine and terbinafine is linked toMAT locus homozygosity and multilocus sequence typing clade 1

Odds, F. C. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00577.x · Cited by 32 · see citing works

Identification of Antifungal Compounds against Multidrug-Resistant Candida auris Utilizing a High-Throughput Drug-Repurposing Screen

Cheng, Y., Roma, J. S., Shen, M., Fernandes, C. M., Tsang, P. S., Forbes, H. J., Boshoff, H. I., Lazzarini, C., Poeta, M. D., Zheng, W., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01305-20 · Cited by 29 · see citing works

Molecular identification and susceptibility profile in vitro of the emerging pathogen Candida kefyr

Gómez‐López, A., Pan, D., Cuesta, I., Alastruey‐Izquierdo, A., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.06.007 · Cited by 24 · see citing works

Antifungal susceptibility testing inCandidaspecies: current methods and promising new tools for shortening the turnaround time

Knabl, L., & Lass‐Flörl, C. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1760841 · Cited by 16 · see citing works

In vitro antifungal susceptibility pattern and ergosterol content in clinical yeast strains

Gómez‐López, A., Buitrago, M. J., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2011) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2010.12.003 · Cited by 12 · see citing works

The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model

Beredaki, M.-I., Arendrup, M. C., Andes, D. R., Mouton, J. W., & Meletiadis, J. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01292-20 · Cited by 10 · see citing works

Utility of Antifungal Susceptibility Testing and Clinical Correlations

Diekema, D. J., & Pfaller, M. A. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5_8 · Cited by 9 · see citing works

Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in Candida species isolated in Africa

Ibe, C., Otu, A. A., & Pohl, C. H. (2025) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2448844 · Cited by 6 · see citing works

Emerging Resistance to Azoles and Echinocandins: Clinical Relevance and Laboratory Detection

Espinel‐Ingroff, A., Pfaller, M. A., Cantón, E., & Pemán, J. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0026-6 · Cited by 5 · see citing works

Incidence, antifungal resistance properties, and virulence traits of candida species isolated from HIV/AIDS Patients from the hospital system in KenyaPreprint

miruka, H. N., Eric, O. O., Musyoki, S., & Awuor, S. O. (2022) · doi:10.1099/acmi.0.000620.v1 · Cited by 4 · see citing works

Comparative In Vitro Activities of Fluconazole, Voriconazole, and MXP-4509 Against Romanian Blood Yeast Isolates

Mareș, M., Năstasă, V., Ramona, F. M., Doroftei, B., & Ştefanache, A. (2011) · Mycopathologia · doi:10.1007/s11046-011-9455-1 · Cited by 2 · see citing works

Susceptibility Test Methods: Yeasts and Filamentous Fungi

Johnson, E. M., & Arendrup, M. C. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0135 · Cited by 1 · see citing works

Susceptibility Test Methods: Yeasts and Filamentous Fungi

Johnson, E. M., & Arendrup, M. C. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0135 · Cited by 1 · see citing works

Oral candida in HIV positive women: influence of oral hygiene, clinical and social factors on the carriage rates and the influence of virulence of the organism on the development of clinical infection

Owotade, F. J. (2014) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)

A Dual-Drug Nanocarrier Strategy for Ocular Fungal Infections: Micelles Embedded in Electrospun Nanofibers

Uzel, E., Durgun, M. E., Aydilek, N., Hacıoğlu, M., Güngör, S., & Özsoy, Y. (2026) · Molecules · doi:10.3390/molecules31081235

Fungal Keratitis: Epidemiology, Diagnosis and Therapy

Rodríguez-García, A., & Amescua, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-19923-2_7

EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole

Arendrup, M. C., Cuenca‐Estrella, M., Lass‐Flörl, C., & Hope, W. W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03890.x · Cited by 122 · see citing works

EUCAST technical note on Amphotericin B

Lass-Flörl, C., Arendrup, M. C., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., Donnelly, P., & Hope, W. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03644.x · Cited by 49 · see citing works

<scp>EUCAST</scp> Technical Note on <i>Candida</i> and micafungin, anidulafungin and fluconazole

Cavling Arendrup, M., Cuenca‐Estrella, M., Lass‐Flörl, C., Hope, W. W., & The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST‐AFST) (2014) · Mycoses · doi:10.1111/myc.12170 · Cited by 43 · see citing works

2010. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr. Fungal Infect. Rep

Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2016)

In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections

Beredaki, M.-I., Arendrup, M. C., Mouton, J. W., & Meletiadis, J. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106291 · Cited by 10 · see citing works